[go: up one dir, main page]

PE20140616A1 - Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri) - Google Patents

Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri)

Info

Publication number
PE20140616A1
PE20140616A1 PE2013002411A PE2013002411A PE20140616A1 PE 20140616 A1 PE20140616 A1 PE 20140616A1 PE 2013002411 A PE2013002411 A PE 2013002411A PE 2013002411 A PE2013002411 A PE 2013002411A PE 20140616 A1 PE20140616 A1 PE 20140616A1
Authority
PE
Peru
Prior art keywords
fluorouracilo
folinic acid
folfiri
irinotecan
composition including
Prior art date
Application number
PE2013002411A
Other languages
English (en)
Inventor
Remi Castan
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46001286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140616(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20140616A1 publication Critical patent/PE20140616A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE CANTIDADES EFICACES DE: A) AFLIBERCEPT; EN COMBINACION CON B) ACIDO FOLINICO; C) 5-FLUOROURACILO (5-FU); Y D) IRINOTECANO, QUE SE ADMINSTRAN DE MODO SIMULTANEO, SECUENCIAL O DE MANERA ESPACIADA. TAMBIEN SE REFIERE A UN KIT QUE COMPRENDE COMPOSICIONES FARMACEUTICAS DE DICHOS PRINCIPIOS ACTIVOS EN RECIPIENTES SEPARADOS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL CANCER COLORRECTAL (CRC) METASTASICO
PE2013002411A 2011-04-26 2012-04-25 Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri) PE20140616A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305490 2011-04-26
EP11306154 2011-09-15

Publications (1)

Publication Number Publication Date
PE20140616A1 true PE20140616A1 (es) 2014-05-24

Family

ID=46001286

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013002411A PE20140616A1 (es) 2011-04-26 2012-04-25 Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri)
PE2017001505A PE20171516A1 (es) 2011-04-26 2012-04-25 Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017001505A PE20171516A1 (es) 2011-04-26 2012-04-25 Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri)

Country Status (39)

Country Link
US (1) US11033606B2 (es)
EP (2) EP3210617A1 (es)
JP (1) JP6114257B2 (es)
KR (2) KR20190088568A (es)
CN (1) CN103608029A (es)
AR (1) AR086051A1 (es)
AU (1) AU2012247530B2 (es)
BR (1) BR112013027356A2 (es)
CA (1) CA2833592A1 (es)
CL (1) CL2013003082A1 (es)
CO (1) CO6811861A2 (es)
CR (1) CR20130547A (es)
CY (1) CY1120382T1 (es)
DK (1) DK2701724T3 (es)
DO (1) DOP2013000248A (es)
EA (1) EA025182B1 (es)
EC (1) ECSP13013044A (es)
ES (1) ES2637074T3 (es)
GT (1) GT201300260A (es)
HR (1) HRP20171216T1 (es)
HU (1) HUE034288T2 (es)
IL (2) IL228947B (es)
JO (1) JO3283B1 (es)
LT (1) LT2701724T (es)
MA (1) MA35130B1 (es)
MX (1) MX341348B (es)
NI (1) NI201300112A (es)
PE (2) PE20140616A1 (es)
PH (1) PH12013502195A1 (es)
PL (1) PL2701724T3 (es)
PT (1) PT2701724T (es)
RS (1) RS56177B1 (es)
SG (2) SG10201610829UA (es)
SI (1) SI2701724T1 (es)
TW (1) TWI599369B (es)
UA (1) UA114708C2 (es)
UY (1) UY34036A (es)
WO (1) WO2012146610A1 (es)
ZA (1) ZA201308821B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AR091967A1 (es) * 2012-08-02 2015-03-11 Sanofi Sa Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
DK3170005T3 (da) 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
MX382673B (es) * 2014-09-16 2025-03-13 Regeneron Pharma Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico.
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CA2992789A1 (en) 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
TW202126293A (zh) 2015-08-21 2021-07-16 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR102652347B1 (ko) 2016-01-25 2024-03-27 사노피 혈장 바이오마커 수준의 측정에 의해 암을 앓고 있는 것으로 의심되는 환자의 아플리베르셉트로의 치료 결과를 예측하는 방법
TWI791467B (zh) 2016-11-02 2023-02-11 英商益普生生物製藥有限公司 使用包含微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）、奧沙利鉑（ｏｘａｌｉｐｌａｔｉｎ）、５-氟尿嘧啶及甲醯四氫葉酸（ｌｅｕｃｏｖｏｒｉｎ）之組合療法治療胃癌
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3099551C (en) 2018-05-10 2025-08-19 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
WO2019229115A1 (en) * 2018-05-30 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2021050094A1 (en) * 2019-09-11 2021-03-18 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790B2 (ja) 1977-11-18 1985-05-17 株式会社日立製作所 光硬化型接着性組成物とそれを用いて被着体を接着する方法
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5399670A (en) 1992-04-30 1995-03-21 Alpha Therapeutic Corporation Solubilization and stabilization of factor VIII complex
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
ATE281469T1 (de) 1993-03-25 2004-11-15 Merck & Co Inc Inhibitor des wachstumsfaktors für gefäss- endothelzellen
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
DE69736860T2 (de) 1996-09-24 2007-05-16 Merck & Co., Inc. Verbindungen zur hemmung der angiogenese durch gentherapie
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19724793A1 (de) 1997-06-06 1998-12-10 Schering Ag D-mutierte Peptide mit VEGF-Rezeptor blockierenden Eigenschaften
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
ATE269357T1 (de) 1999-04-28 2004-07-15 Univ Texas Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
DE19938724A1 (de) 1999-08-16 2001-02-22 Tetra Laval Holdings & Finance Vorrichtung zur Herstellung von Kunststoffbehältern mittels Streckblasformen
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
GT200100079A (es) 2000-05-10 2001-12-31 Metodo para regular la angiogenesis utilizando proteina ryk
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040023864A1 (en) 2001-05-09 2004-02-05 Steve Roczniak Method of regulating angiogenesis using ryk protein
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
MXPA04008484A (es) 2002-03-01 2004-12-06 Pharmacia Italia Spa Forma polimorfica cristalina de clorhidrato de irinotecano.
JP2004006671A (ja) 2002-03-22 2004-01-08 Sanyo Electric Co Ltd 電荷結合素子およびその製造方法
US7052691B2 (en) 2003-03-28 2006-05-30 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking VEGF-mediated activity
PT2335725T (pt) 2003-04-04 2017-01-06 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US7300654B2 (en) 2003-05-28 2007-11-27 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection in high risk keratoplasty patients
MXPA05008973A (es) 2003-05-28 2006-02-22 Regeneron Pharma Metodo de tratamiento de rechazo de trasplante de cornea.
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050196340A1 (en) 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
US20050112061A1 (en) 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
JP4812431B2 (ja) 2003-08-14 2011-11-09 富士通株式会社 コンピュータ装置
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
EP1529620B1 (fr) 2003-11-06 2009-02-25 Nestlé Waters Management & Technology Procédé de fabrication de contenants en résine polyester
CA2545187A1 (en) 2003-11-10 2005-05-26 Greenville Hospital System Vegf receptor antagonists
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
WO2005123104A2 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
US20050281822A1 (en) 2004-06-18 2005-12-22 Cedarbaum Jesse M Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
JP4807802B2 (ja) 2004-07-30 2011-11-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆ媒介性活性をブロックすることによるｉ型糖尿病を処置する方法
WO2006047325A1 (en) 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
FR2878749B1 (fr) 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
WO2006086544A2 (en) 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
EP1855708A1 (en) 2005-03-11 2007-11-21 Regeneron Pharmaceuticals, Inc. Treating anemia by inhibition of vegf
DK1861116T3 (en) 2005-03-25 2015-11-09 Regeneron Pharma VEGF antagonist formulations
RU2414924C2 (ru) 2005-08-12 2011-03-27 Ридженерон Фармасьютикалз, Инк. Способы лечения заболеваний антагонистами vegf
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
PT2944306T (pt) 2006-06-16 2021-02-15 Regeneron Pharma Formulações antagonistas de vegf adequadas para administração intravitreal
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US20100216168A1 (en) 2007-03-23 2010-08-26 Precision Therapeutics, Inc. Methods for evaluating angiogenic potential in culture
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN100546578C (zh) * 2007-08-10 2009-10-07 河北医科大学 一种抗癌药物组合物及其在制备抗癌药物中的应用
ES2684340T3 (es) 2007-10-04 2018-10-02 Onyx Therapeutics, Inc. Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
CA2705792A1 (en) 2007-11-30 2009-06-11 Milan Radovich Vegf polymorphisms and anti-angiogenesis therapy
EP2143542A1 (fr) 2008-07-07 2010-01-13 Nestec S.A. Procédé et dispositif de conditionnement d'un liquide alimentaire
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
US20100047314A1 (en) 2008-08-22 2010-02-25 Osteogenex Inc. Folinic acid derivatives for promoting bone growth
WO2010042903A1 (en) 2008-10-09 2010-04-15 Alfagene Bioscience, Inc Use and identification of biomarkers for gastrointestinal diseases
US20120003641A1 (en) 2008-11-05 2012-01-05 Graham Robert R Genetic polymorphisms in age-related macular degeneration
AU2010230346A1 (en) 2009-03-31 2011-07-28 Roche Glycart Ag Treatment of cancer with a humanized anti-EGFR IgG1antibody and irinotecan
US20120100134A1 (en) 2009-04-24 2012-04-26 University Of Southern California Genetic variants in angiogenesis pathway associated with clinical outcome
JP5732458B2 (ja) 2009-07-31 2015-06-10 アムコー リミテッド 高温充填容器
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2012123227A1 (en) 2011-02-23 2012-09-20 Sanofi Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
JP6019790B2 (ja) 2012-06-19 2016-11-02 富士電機株式会社 接合方法及び接合部材
AR091967A1 (es) 2012-08-02 2015-03-11 Sanofi Sa Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept
DK3170005T3 (da) * 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
KR102652347B1 (ko) 2016-01-25 2024-03-27 사노피 혈장 바이오마커 수준의 측정에 의해 암을 앓고 있는 것으로 의심되는 환자의 아플리베르셉트로의 치료 결과를 예측하는 방법

Also Published As

Publication number Publication date
EP3210617A1 (en) 2017-08-30
TW201247220A (en) 2012-12-01
IL228947B (en) 2018-01-31
NZ617573A (en) 2015-11-27
DOP2013000248A (es) 2014-02-28
AU2012247530A1 (en) 2013-05-02
JP6114257B2 (ja) 2017-04-12
BR112013027356A2 (pt) 2016-11-29
LT2701724T (lt) 2017-09-11
GT201300260A (es) 2015-02-09
JP2014513089A (ja) 2014-05-29
HUE034288T2 (en) 2018-02-28
UA114708C2 (uk) 2017-07-25
EA025182B1 (ru) 2016-11-30
NI201300112A (es) 2014-02-28
ES2637074T3 (es) 2017-10-10
EA201391577A1 (ru) 2014-03-31
CY1120382T1 (el) 2019-07-10
DK2701724T3 (en) 2017-09-11
HRP20171216T1 (hr) 2017-10-20
PE20171516A1 (es) 2017-10-20
CR20130547A (es) 2014-02-18
IL228947A0 (en) 2013-12-31
PL2701724T3 (pl) 2017-11-30
JO3283B1 (ar) 2018-09-16
MX2013012387A (es) 2014-12-05
MX341348B (es) 2016-08-17
IL257179A (en) 2018-03-29
SG10201610829UA (en) 2017-02-27
KR102002653B1 (ko) 2019-07-24
ECSP13013044A (es) 2014-01-31
RS56177B1 (sr) 2017-11-30
SG194613A1 (en) 2013-12-30
KR20190088568A (ko) 2019-07-26
EP2701724A1 (en) 2014-03-05
TWI599369B (zh) 2017-09-21
US11033606B2 (en) 2021-06-15
AU2012247530B2 (en) 2017-05-11
UY34036A (es) 2012-11-30
US20140051642A1 (en) 2014-02-20
PH12013502195A1 (en) 2022-04-08
ZA201308821B (en) 2015-01-28
CO6811861A2 (es) 2013-12-16
CA2833592A1 (en) 2012-11-01
WO2012146610A1 (en) 2012-11-01
PT2701724T (pt) 2017-08-18
EP2701724B1 (en) 2017-05-24
CN103608029A (zh) 2014-02-26
KR20140036193A (ko) 2014-03-25
AR086051A1 (es) 2013-11-13
SI2701724T1 (sl) 2017-10-30
CL2013003082A1 (es) 2014-05-16
MA35130B1 (fr) 2014-05-02

Similar Documents

Publication Publication Date Title
PE20140616A1 (es) Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri)
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
HK1247850A1 (zh) Pd-1 拮抗剂与egfr 抑制剂的组合
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1213552A1 (zh) 经取代的苯化合物
GB201106743D0 (en) Novel compounds
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
PE20091655A1 (es) Farmaco para el cancer de higado
EA201690159A1 (ru) Способы и композиции для лечения рака
CL2015001849A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpos fármaco, y usos de estos
WO2014011077A3 (ru) Фармацевтический состав, обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты)
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
TN2013000430A1 (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)

Legal Events

Date Code Title Description
FC Refusal